Supernova Invest / Heal Capital take majority stake in Gleamer

FRANCE Healthcare Services / Health Tech REV €5–25M

Context

Gleamer raised €27 million in Series B funding to broaden its AI solution portfolio and accelerate global commercial development. The strategic plan involves expanding the software suite to include CT scans and mammography, aiming to cover 70% of radiologists' daily diagnostic needs. A significant portion of the capital is earmarked for strengthening commercial and technical teams in Europe and the United States, as well as deepening strategic partnerships with global medical imaging equipment manufacturers (OEMs).

Gleamer, which reported an EBITDA margin of [members only] in 2023, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average observed in the Healthcare & Pharma sector (16.0x in 2023).

-> Deep-dive in Healthcare & Pharma market trends

Target

Gleamer is a leading French MedTech company specializing in artificial intelligence for medical imaging. Its "Copilot" platform provides automated diagnostic assistance for radiologists across multiple modalities, including X-ray, Mammography, and MRI. Prior to this acquisition, Gleamer consolidated the market by acquiring Pixyl and Caerus Medical in 2025, expanding its expertise into neuro and lumbar MRI. The company serves over 700 clients in 44 countries, with its solutions supporting over 25 clinical indications.

Ent. Value

[members only]

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2023

2022

Other operations with Gleamer

Other operations with Gleamer
Date	Acquirer	Target	Country	Sector
03/2026	RADNET	GLEAMER	FRANCE	Health Tech

Similar deals in Healthcare Services

Similar deals in Healthcare Services
Date	Acquirer	Target	Country	Sector
09/2023	CERBA HEALTHCARE	CIRION BIOPHARMA RESEARCH	CANADA	CRO / Clinical Trials
09/2023	PERMIRA	ERGOMED	UNITED KINGDOM	CRO / Clinical Trials
06/2022	ASTORG	OPEN HEALTH	UNITED STATES	Healthcare Services
11/2020	KERSIA	SOPURA	BELGIUM	Sterilization & Hygiene
10/2020	IK PARTNERS	KERSIA	FRANCE	Sterilization & Hygiene
05/2020	CLAYTON, DUBILIER & RICE (CD&R)	HUNTSWORTH	UNITED KINGDOM	Healthcare Services
03/2020	LDC	AGENTIS HEALTH GROUP	UNITED KINGDOM	Healthcare Services
01/2018	SPECTRIS	CONCEPT LIFE SCIENCES	UNITED KINGDOM	CRO / Clinical Trials
04/2016	CHARLES RIVER LABORATORIES	WIL RESEARCH	UNITED STATES	CRO / Clinical Trials
04/2015	CLINIGEN GROUP	IDIS	UNITED KINGDOM	Healthcare Services

REFERENCES

Revenue range: REV €5–25M

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Gleamer by Supernova Invest / Heal Capital are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: gleamer

Acquirer: supernova invest

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Gleamer, a French company specialised in Health Tech, by Supernova Invest and Heal Capital in 2023. Ownership has since evolved, leading to a subsequent transaction with Radnet in March 2026 (see the dedicated deal page for details).

What was Gleamer’s revenue at the time of the deal?

At the time of the transaction, Gleamer’s annual revenue was estimated within the €5–25M range (FY 2023). Detailed financial figures are available to members.

How does the valuation of Gleamer compare to benchmarks in the Healthcare & Pharma sector?

Transaction multiples for this specific deal are exclusively reserved for mynth members. Nevertheless, transactions tracked by mynth in this sector reveal an average benchmark multiple of 16.0x EBITDA during 2023.

What sources support the information on this transaction?

Transaction data and operational intelligence were compiled from independent financial press reporting by specialized M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.